HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
JTP 4819
a prolyl endopeptidase inhibitor; structure given in first source
Also Known As:
2-((2-(hydroxyacetyl)-1-pyrrolidinyl)carbonyl)-N-(phenylmethyl)-1-pyrrolidinecarboxamide; JTP-4819
Networked:
6
relevant articles (
3
outcomes,
2
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyrrolidines: 115
JTP 4819: 6
Experts
1.
Lehtonen, Sárka
: 1 article (12/2006)
2.
Männistö, Pekka T
: 1 article (12/2006)
3.
Puttonen, Katja A
: 1 article (12/2006)
4.
Raasmaja, Atso
: 1 article (12/2006)
Related Diseases
1.
Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
06/03/1996 - "
These results suggest that JTP-4819 ameliorates memory impairment due to middle cerebral artery occlusion by restoring the cortical TRH content.
"
06/03/1996 - "
The prolonged escape latency in the Morris water maze task in rats with middle cerebral artery occlusion was also significantly reduced by administration of JTP-4819 (0.3 and 1 mg/kg p.o.).
"
06/03/1996 - "
Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion.
"
06/03/1996 - "
Administration of JTP-4819 (0.1 and 1 mg/kg p.o for 7 days) significantly prolonged passive avoidance latency, while the latency of rats with middle cerebral artery occlusion receiving the vehicle was significantly shorter than that of sham-operated rats.
"
2.
Amnesia (Dissociative Amnesia)
09/01/1995 - "
In the one-trial passive avoidance test in rats with scopolamine-induced amnesia, JTP-4819 significantly prolonged the retention time when administered orally at doses of 1 and 3 mg/kg 1 hr before acquisition or at 3 and 10 mg/kg 1 hr before retention.
"
09/01/1995 - "
In addition, coadministration of JTP-4819 and substance P, arginine-vasopressin or thyrotropin-releasing hormone (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced amnesia.
"
3.
Memory Disorders (Memory Loss)
03/01/1997 - "
Administration of JTP-4819 (1 mg/kg, p.o.) for 14 days improved this memory deficit in aged rats, as shown by the decrease in escape latency and path length.
"
4.
Alzheimer Disease (Alzheimer's Disease)
02/01/1997 - "
Taken together, these unique and potent pharmacological actions of JTP-4819 suggest that it may have the potential to be used for treating Alzheimer's disease.
"
01/01/1998 - "
In this report, the pharmacological actions of JTP-4819, a novel specific prolyl endopeptidase (PEP) inhibitor devised for the treatment of Alzheimer's disease, are reviewed with respect to its effects on PEP activity, neuropeptidergic and cholinergic neurons, and memory-related behavior in rats.
"
02/01/1997 - "
A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease.
"
02/01/1997 - "
The pharmacological actions of JTP-4819, a new prolyl endopeptidase (PEP) inhibitor targeted for the treatment of Alzheimer's disease, are reviewed with respect to its effects on PEP activity, brain neurotransmitters, and memory-related behaviour in rats.
"
5.
Neuroblastoma
12/01/2006 - "
We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.
"
Related Drugs and Biologics
1.
Scopolamine (Hyoscine)
2.
Thyrotropin-Releasing Hormone (Protirelin)
3.
Substance P
4.
Arginine Vasopressin (Argipressin)
5.
Prolyl Oligopeptidases
6.
Neurotransmitter Agents (Neurotransmitter)
7.
Reactive Oxygen Species (Oxygen Radicals)
8.
Oxidopamine (6 Hydroxydopamine)
9.
Glyceraldehyde-3-Phosphate Dehydrogenases (GAPD)
10.
Cytarabine (Cytosar-U)